Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral...
Table: Antiviral Effect of MAU868 vs. Placebo at Week 36 Table: Antiviral Effect of MAU868 vs. Placebo at Week 36New...
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients...
- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis...
Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022...
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase...
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fuss Brands Corp. (OTC Markets: FBDS) announced today the signing of an...
THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022...
TORONTO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) (OTCQX:VHIBF) is pleased to announce...
SAN LEANDRO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development...
SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing...
EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker...
ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a...
WARSAW, Ind., Nov. 04, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on...
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and...
Kabuki Syndrome Foundation Annual Conference11th Drug Discovery Strategic SummitInv€$tival Showcase LSX Leaders 2022Jefferies London Healthcare Conference 2022MADRID, Spain and BOSTON,...
Six-month outcomes are expected in second quarter of 2023DALLAS, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a...
Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference...
Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points...